FDA PMA

クロロゲン酸インシチューハイブリデーション、核酸増幅、Her2/Neu遺伝子、乳がん

PMA番号：P190031 · 2026-08-25

申請者Ventana Medical Systems, Inc.

決定日2026-08-25

PMA番号P190031

製品コードNYQ

デバイスクラスクラス2

診療科P

規制番号21 CFR 8

諮問委員会PA （注：原文中未提供具体的医疗设备监管文本内容，因此无法进行翻译。请提供具体的文本内容以便进行翻译。）

医療機器の概要

Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer is the device name listed in this FDA 510(k) record. The listed applicant is Ventana Medical Systems, Inc.. It received FDA 510(k) clearance on 2026-08-25. The device is classified under product code NYQ. It was reviewed by the PA advisory panel.

よくある質問

What is the Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer?

Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer is a medical device that received FDA 510(k) clearance on 2026-08-25. The listed applicant is Ventana Medical Systems, Inc..

When did Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer receive FDA 510(k) clearance?

The clearance date for Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer can be found in the official FDA records.

Who is the listed applicant for Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer?

The FDA 510(k) record lists Ventana Medical Systems, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer?

The FDA product code for Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer is NYQ.

公式ソース

FDAデータベースで見る →

データはFDA Open APIから取得しています。最新かつ権威ある情報については、常に公式レコードを参照してください。

医療機器の概要

よくある質問

関連する臨床試験

公式ソース